🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Spain / NCT06698172
Recruiting Not applicable

Motor Performance Improvement After Visual Rehabilitation

NCT06698172 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2024-11-29
Last updated
2024-11-20

Condition(s) studied

Visual Field LossBalanceBrain InjuryMotor Performance

Investigational drug(s) / intervention(s)

Virtual Reality rehabilitation

Virtual Reality rehabilitation: The study includes 12 weekly 45-minute visual rehabilitation sessions using a Virtual Reality device with Visionary Sport software. Originally designed for sports visual training, this software features gamified exercises to improve visual response times under professional supervision. Activities include games to enhance fixation, ocular motility, peripheral vision, and vergence. The "Peripheral Attention" activity trains reaction times to static stimuli perceived in the peripheral retina, adjustable to the patient's visual field defect. Stimuli can be placed at 10, 20, or 30 degrees in the peripheral field. The VR headset (Vive Focus 3) includes an eye tracker to monitor and adapt stimuli based on patient performance. Patients also perform 30 minutes of daily exercises at home, using proprietary software and Tobii 4C and 5C eye-tracking devices for ocular monitoring.

Study summary

Acquired brain injury" refers to brain damage that impacts neurological processing, making daily activities challenging and often causing vision issues like binocular dysfunction, oculomotor problems, and visual field loss. In Spain, visual rehabilitation is limited, although it is more common in other countries.

These patients generally need an interdisciplinary approach involving professionals like physiotherapists and optometrists and often face mobility, balance, and spatial perception difficulties. Treatment tools include lenses, prisms, and technologies like virtual reality (VR). The Visionary VR program, presented by Dr. Portela, has shown promising results in visual field recovery by stimulating the affected area.

Visual rehabilitation is based on brain plasticity and involves three key strategies:

Prisms to expand the visual field. Compensatory therapy to improve eye movement. Restitution therapy to restore the visual field.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Adult subjects diagnosed with acquired brain injury either from a stroke or trauma. * Subjects without cognitive impairment. * Subjects without pre-existing musculoskeletal disorders prior to the acquired brain injury. * Subjects without hemineglect. * Subjects with more than 6 months of progression since the brain injury. * Subjects who have an electronic device such as a computer and internet access to perform the exercises at home. * Subjects with altitudinal visual field loss, hemianopia, or quadrantanopia with the central field preserved and at least 0.5 visual acuity. Exclusion Criteria: * Not signing the informed consent. * Previous severe mental pathology to eliminate possible confounding factors if their daily activities are already affected. * Uncontrolled epilepsy. * Subjects with glaucoma or retinal pathologies affecting the visual field. * Subjects with previous ocular surgery (cataract or refractive surgery) with less than 6 months of progression. * Subjects who are not stable in any associated clinical pathology or otherwise diagnosed. * Subjects who have previously undergone visual rehabilitation for the field defect. * Not performing the proposed home exercises.

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
University of Zaragoza Zaragoza Zaragoza Recruiting
University of Zaragoza Zaragoza Zaragoza Recruiting

More Instituto de Investigación Sanitaria Aragón trials in Spain

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06698172 on ClinicalTrials.gov ↗ ← All trials in Spain